Rise In Cardiovascular Diseases Driving The Growth Of The Market Due To Increasing Prevalence And Demand For Heart-Related Treatments: Key Factor Driving The Growth In The Cardiotonic Agents Market

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics._x000D_
_x000D_
What Is the Expected Cardiotonic Agents Market Size During the Forecast Period?_x000D_
The market size for cardiotonic agents has witnessed a rapid expansion in the recent past. The sector, which was valued at $2.78 billion in 2024, will increase to $3.14 billion in 2025, with a compound annual growth rate (CAGR) of 12.9%. Factors contributing to the growth during the historic period include an increase in heart failure cases, a rising elderly population, higher incidence of coronary artery disease, a surge in sedentary lifestyles, and an increasing weight of hypertension and diabetes._x000D_
_x000D_
The market for cardiotonic agents is predicted to witness significant expansion in the coming years, reaching $5.06 billion by 2029 with a CAGR of 12.6%. Various factors contributing to this growth include increased cardiovascular death rates, a surge in clinical trials aiming for enhanced cardiotonic recipes, increased collaboration between public and private sectors in cardiovascular drug advancement, rising hospital admissions due to heart-related issues and augmenting call for bespoke cardiovascular treatments. Looking into the future, trends like developing peptide-fuelled cardiotonic agents, the creation of dual-action drugs, the inclusion of pharmacogenomics, innovation in injectable depot formulations and combo therapies are anticipated._x000D_
_x000D_
Purchase the full report for exclusive industry analysis:_x000D_
https://www.thebusinessresearchcompany.com/customise?id=24184&type=smp_x000D_
_x000D_
What Are the High-Growth Segments in the Cardiotonic Agents Market?_x000D_
The cardiotonic agents market covered in this report is segmented -_x000D_
_x000D_
1) By Drug Type: Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, Other Drug Types_x000D_
2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations_x000D_
3) By Dosage Form: Tablet, Solution, Other Dosage Forms_x000D_
4) By Application: Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension, Other Applications_x000D_
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies_x000D_
_x000D_
Subsegments:_x000D_
1) By Digitalis Glycoside: Digoxin, Digitoxin, Lanatoside C_x000D_
2) By Phosphodiesterase Inhibitors: Milrinone, Enoximone, Amrinone_x000D_
3) By Cardioprotectants: Coenzyme Q10, Dexrazoxane, Trimetazidine_x000D_
4) By Sympathomimetic Agents: Dobutamine, Dopamine, Norepinephrine_x000D_
5) By Other Drug Types: Levosimendan, Omecamtiv Mecarbil, Cilostazol_x000D_
_x000D_
Get your free sample here:_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=24184&type=smp_x000D_
_x000D_
What Key Drivers Are Expected to Influence Future Cardiotonic Agents Market Growth?_x000D_
The escalating rate of cardiovascular diseases is poised to spur the expansion of the cardiotonic agents market. Cardiovascular diseases, also known as CVDs, include a variety of disorders impacting the heart and blood vessels, such as coronary artery disease, heart failure, arrhythmias, and stroke. The surge in these diseases can largely be attributed to unhealthy eating habits, featuring excessive consumption of saturated fats, trans fats, salt, and added sugars, leading to obesity, hypertension, and high cholesterol levels. Cardiotonic agents amplify the efficiency and the power of heart muscle contractions, which enhances blood circulation and alleviates symptoms in numerous cardiovascular diseases. As an illustration, in December 2023, the Australian Institute of Health and Welfare, a government agency in Australia, reported that medically certified deaths due to coronary heart disease (CHD) in Australia saw an upsurge from 14,100 in 2021 to 14,900 in 2022. Consequently, the escalating prevalence of cardiovascular diseases is fuelling the expansion of the cardiotonic agents market._x000D_
_x000D_
Which Companies Hold the Largest Share Across Different Cardiotonic Agents Market Segments?_x000D_
Major companies operating in the cardiotonic agents market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Fresenius Kabi, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Alchem International Private Ltd, Farbe Firma Private Limited, Salius Pharma Pvt. Ltd., Johnlee Pharmaceuticals Pvt. Ltd., Healthy Life Pharma Pvt Ltd, Anwita Drugs, Varion Lifesciences, Deccan Nutraceuticals Pvt. Ltd._x000D_
_x000D_
What Are the Major Trends Shaping the Cardiotonic Agents Market?_x000D_
Prominent businesses in the cardiotonic agents industry are concentrating on developing progressive products like short-term inotropic medications, designed to improve cardiac function in severe heart failure or cardiogenic shock cases. These drugs temporarily increase the heart's ability to contract, leading to improved cardiac output. For example, in June 2023, Hikma Pharmaceuticals plc, a pharmaceutical firm based in the UK, introduced Dobutamine Injection, USP, packed in a 250 mg/20 mL vial. This injection caters to adults dealing with cardiac decompensation resulting from diminished heart contractility often linked to heart disease or post-cardiac surgery. It functions by triggering beta-1 receptors, which in turn magnify heart muscle contractility and cardiac output swiftly (between 1 - 2 minutes). The injection is typically administered intravenously in a closely monitored hospital environment._x000D_
_x000D_
Get the full report for exclusive industry analysis:_x000D_
https://www.thebusinessresearchcompany.com/report/cardiotonic-agents-global-market-report_x000D_
_x000D_
What Are the Emerging Geographies for The Cardiotonic Agents Market Growth?_x000D_
North America was the largest region in the cardiotonic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiotonic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
Frequently Asked Questions:_x000D_
1. What Is the Market Size and Growth Rate of the Cardiotonic Agents Market?_x000D_
2. What is the CAGR expected in the Cardiotonic Agents Market?_x000D_
3. What Are the Key Innovations Transforming the Cardiotonic Agents Industry?_x000D_
4. Which Region Is Leading the Cardiotonic Agents Market?_x000D_
_x000D_
Why This Report Matters:_x000D_
_x000D_
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors._x000D_
_x000D_
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends._x000D_
_x000D_
Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.